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based on the underlying causative geneDianna M. Milewicz, MD, PhD, Ellen S. Regalado, MS, and Dong-chuan Guo, PhDThoracic aortic aneurysms leading to acute aortic dissections
(TAADs) are a common cause of premature death in the
United States.1,2 The natural history of ascending aortic
aneurysms is to progressively enlarge over time and
ultimately lead to life-threatening acute aortic dissection or
aortic rupture. Although medical treatments can slow the en-
largement of ascending aortic aneurysms, the mainstay of
prevention of aortic dissection is surgical repairwhen the aor-
tic diameter expands to 5.5 cm ormore.2 However, aortic dis-
sections occur in some patients who have little or no aortic
enlargement. In fact, data from the International Registry
of Aortic Dissections indicate that nearly 60% of aneurysms
dissect at aortic diameters of less than 5.5 cm.3 Because ap-
proximately one half of patients with acute ascending aortic
dissection die suddenly without reaching a hospital, prevent-
ing premature deaths necessitates identifying subjects at risk
for aortic dissection, carefully monitoring the diameter of the
ascending aorta, and performing timely elective surgical
repair. Therefore improved clinical predictors are needed
not only to identify who is at risk for TAADs but also to de-
termine the aortic diameter that justifies the risk of surgical
repair of a thoracic aortic aneurysm to prevent an acute aortic
dissection.
Hypertension and the presence of a congenital bicuspid
aortic valve (BAV) are risk factors for the disease, but a ge-
netic predisposition also plays a prominent role in etiology.2
For many years, it has been known that patients with Marfan
syndrome (MFS), an autosomal dominant syndrome with
skeletal and ocular features, are highly predisposed to
TAADs.4 MFS results from mutations in FBN1, which
encodes fibrillin-1, a component of elastin-associated micro-
fibrils.5 Loeys–Dietz syndrome (LDS) also predisposes
patients to TAADs, along with craniofacial abnormalities,
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beyond the ascending aorta is widespread but primarily
involves the thoracic arterial circulation, including the
coronary, subclavian, pulmonary, and intercostal arteries,
and surgical intervention is generally successful.8 LDS
results from mutations in either the transforming growth
factor b receptor type I or II genes (TGFBR1 or TGFBR2).
Clinical studies of MFS and LDS have provided the first
evidence that the timing of surgical repair of thoracic aortic
aneurysms can be dictated by the underlying mutated gene
causing the disease. Both syndromes lead to aneurysms
involving the aortic root (defined as the segment of the
ascending aorta extending from the valvular annulus to the
sinotubular junction and including the sinuses of Valsalva).
Patients with MFS with FBN1 mutations are at a low risk
for acute dissections until the aorta is greater than 5.5 cm in
diameter.9 In contrast, accumulating data from our research
and that of others suggest that patients with a TGFBR2
mutation (patients with either LDS or a family history of
TAADs [FTAAD], as described below) experience aortic
dissections with minimal enlargement of the aorta, leading
to the recommendation that patients with a TGFBR2 muta-
tion undergo surgical repair of an aortic aneurysm when the
diameter reaches 4.2 cm.2 In addition to determining the
risk of aortic dissection at a given diameter, current data sug-
gest that the underlyingmutation also dictates the risk for fur-
ther vascular disease beyond the ascending thoracic aorta.
For example, patients with TGFBR2 mutations are at a high
risk for aneurysms and dissections beyond the aortic root,
including cerebrovascular disease,7,10 whereas the risk for
involvement of other arteries is low in patients with MFS.
We and others have determined that up to 19% of patients
with TAADs without a genetic syndrome have FTAAD, in-
dicating a significant genetic component to this disease.11,12
FTAAD is primarily inherited in families as an autosomal
dominant condition with decreased penetrance, primarily
in women.12,13 The familial aortic disease is variable in its
expression of thoracic aortic disease, including varying age
of disease onset, severity of presentation, and whether the
aortic aneurysm involves the aortic root or the ascending
aorta, sparing the root. There is interfamilial variability in
FTAAD, with a subset of families with members who
experience aortic dissections with little to no enlargement
of the ascending aorta.13 Additionally, variability in these
families is evident in the clinical features that are associated
with or segregate with the thoracic aortic disease in family
members, which can include intracranial aneurysms, iliac
and popliteal artery aneurysms, occlusive vascular diseasesry c December 2010
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aortic aneurysms, patent ductus arteriosus (PDA), and bicus-
pid aortic valve (BAV).14,15
We have identified TGFBR1 and TGFBR2mutations in ap-
proximately 3% to 5% of FTAAD families whose members
do not have features of LDS, suggesting a similar pathogene-
sis for disease in these FTAAD families.8,16,17 In FTAAD
families with TGFBR2 mutations, aortic dissections occur
with minimal enlargement of the aortic root. Therefore the
recommendation for surgical repair of an aortic aneurysm
when the diameter reaches 4.2 cm applies to both patients
with LDS and patients with FTAAD. Interestingly, FTAAD
can result from mutations in either TGFBR1 or TGFBR2,
but data are emerging in these families to support the notion
that there are differences in vascular disease presentation
and risk for dissection based on whether TGFBR1 or
TGFBR2 is the causative gene.10
We and others have begun to identify additional genes for
FTAAD. We have determined that the most frequently mu-
tated gene is the smooth muscle cell (SMC)–specific isoform
of a-actin, ACTA2, which is responsible for 10% to 14% of
familial thoracic aortic disease.15 A large French family was
used by other investigators to map and identify mutations in
the SMC-specific isoform of b-myosin heavy chain,
MYH11.18 These genes encode the major proteins found in
SMC contractile units, which function to contract the
SMC to withstand the stress of pulsatile blood flow and reg-
ulate flow and pressure. We have hypothesized that proper
SMC contraction is implicated in maintaining the structural
integrity of the ascending aorta, with disruption of SMC
contractile function leading to TAADs.19
Analysis of thoracic aortic disease in patients with ACTA2
mutations reveals some clinical features of the disease. The
penetrance of TAADs in patients with ACTA2 mutations is
approximately 50%; that is, half of the ACTA2mutation car-
riers do not have thoracic aortic disease. The low penetrance
of ACTA2 mutations differs from what is observed at other
identified loci and genes for FTAAD, with an age-related
penetrance that is higher.16,20 The majority of the patients
with ACTA2 mutations presented with acute ascending
(type A) or descending (type B) aortic dissections, and 16
of the 24 deaths were due to type A dissections. Two
patients experienced type A dissections at documented
ascending aortic diameters of 4.5 and 4.6 cm, respectively,
whereas 11 patients had dissections at aortic diameters of
greater than 5.0 cm. Aortic dissections occurred in 3
patients less than 20 years of age, and 2 women died of
dissections postpartum. Three young men had type B
dissections complicated by rupture or aneurysm formation
at 13, 16, and 21 years of age. Finally, a rare patient with
ACTA2 mutation can present with BAV or PDA.
Investigations into other vascular disease beyond thoracic
aortic disease revealed that ACTA2mutations predispose not
only to TAADs but also to occlusive vascular diseases, in-The Journal of Thoracic and Cacluding early-onset coronary artery disease, stroke, and
Moyamoya disease (a rare stroke syndrome).21 An investi-
gation into occlusive vascular diseases in patients with
FTAAD with ACTA2 mutations was initiated when we ob-
served that all mutation carriers in a family had livedo retic-
ularis, a skin rash caused by occlusion of the dermal arteries,
irrespective of whether they had aortic disease.15 Addition-
ally, we noted that the vasa vasorum in the aortas of patients
with ACTA2 mutations were occluded due to SMC prolifer-
ation. Subsequent linkage and association studies confirmed
that ACTA2 mutations also cause occlusive vascular dis-
eases, such as coronary artery disease and stroke, before
the age of 55 years in men and 60 years in women. More-
over, a subset of ACTA2mutations also predispose to Moya-
moya disease, a rare cerebrovascular syndrome
characterized by bilateral occlusion or stenosis of the termi-
nal internal carotid arteries and the formation of collateral
vessel networks at the base of the brain, so-called Moya-
moya vessels.22,23 These data demonstrate that diffuse
vascular disease resulting from either occluded or dilated
arteries can be caused by a mutation in a single gene and
have direct implications for clinical management of
patients with ACTA2 mutations.
MYH11 mutations are a rare cause of FTAAD and only
occur in families in which 1 or more members with TAADs
also have PDA.18,24,25 Limited data of thoracic aortic disease
in patients withMYH11mutations suggest that these patients
have aneurysms involving the ascending aorta and
can experience aortic dissections with aortic diameters of
4.4 cm.25
Because fewer than 20% of FTAAD families have muta-
tions in one of the known genes, specific management for the
majority of FTAAD families is still not defined. For these
families, we recommend that the aortic disease presentation
in the affected family members be assessed, along with other
vascular disease or clinical features, and that the manage-
ment be based on this assessment. If family members have
experienced dissections at aortic diameters of less than 5.0
cm, then surgical repair for other affected family members
at diameters of less than 5.0 cm should be considered. In
families with TAADs associated with BAV, studies have
indicated that the component features, BAV and TAADs,
are independent manifestations of a single-gene defect.14
Therefore family members need to have routine aortic
imaging, irrespective of whether BAV is present.
In summary, as novel FTAAD genes are discovered,
clinical features associated with each gene are identified
that inform the clinical management of patients based on
the underlying genetic mutation. Based on these findings,
we are recommending that if the underlying gene causing
the predisposition to thoracic aortic disease is identified in
a patient or family, the management of the aortic disease
and risk for additional vascular diseases be based on the
causative gene.rdiovascular Surgery c Volume 140, Number 6S S3
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